NCT03084289View on ClinicalTrials.gov

A Study to Assess the Safety and Immunogenicity of a Candidate Malaria Vaccine Using Novel Routes of Administration

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

March 28, 2017

Primary Completion Date

July 6, 2020

Study Completion Date

July 6, 2020

Conditions
Malaria
Interventions
BIOLOGICAL

ChAd63-METRAP

The candidate vaccine applicable to the clinical trial is the Chimpanzee adenovirus 63 expressing Multiple epitopes and thrombospondin related adhesion protein.

BIOLOGICAL

MVA ME-TRAP

The candidate vaccine applicable to the clinical trial is the Modified Vaccinia virus Ankara expressing Multiple epitopes and thrombospondin related adhesion protein.

Trial Locations (1)

OX3 7LE

Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford

All Listed Sponsors
lead

University of Oxford

OTHER

NCT03084289 - A Study to Assess the Safety and Immunogenicity of a Candidate Malaria Vaccine Using Novel Routes of Administration | Biotech Hunter | Biotech Hunter